New research has found that Cannnabidiol is active against Gram-positive bacteria, including those responsible for many serious infections (such as Staphyloccocus aureus and Streptococcus pneumoniae), with potency similar to that of established antibiotics such as vancomycin or daptomycin.
The research is presented at ASM Microbe, the annual meeting of the American Society for Microbiology.
Cannabidiol, the main non-psychoactive chemical compound extracted from cannabis and hemp plants, has been approved by FDA for the treatment of a form of epilepsy, and is being investigated for a number of other medical conditions, including, anxiety, pain and inflammation. While there is limited data to suggest Cannabidiol can kill bacteria, the drug has not been thoroughly investigated for its potential as an antibiotic.
Work led by Dr Mark Blaskovich at The University of Queensland’s Institute for Molecular Bioscience’s Centre for Superbug Solutions, in collaboration with Botanix Pharmaceuticals Ltd, an early stage drug discovery company investigating topical uses of synthetic cannabidiol for a range of skin conditions, found that Cannabidiol was remarkably effective at killing a wide range of Gram-positive bacteria, including bacteria that have become resistant to other antibiotics, and did not lose effectiveness after extended treatment.
“Given cannabidiol’s documented anti-inflammatory effects, existing safety data in humans, and potential for varied delivery routes, it is a promising new antibiotic worth further investigation,” said Dr. Blaskovich. “The combination of inherent antimicrobial activity and potential to reduce damage caused by the inflammatory response to infections is particularly attractive.”
Importantly, the drug retained its activity against bacteria that have become highly resistant to other common antibiotics. Under extended exposure conditions that lead to resistance against vancomycin or daptomycin, Cannabidiol did not lose effectiveness. Cannabidiol was also effective at disrupting biofilms, a physical form of bacteria growth that leads to difficult-to-treat infections.
The project was co-funded by Botanix and Innovation Connections, an Australian government grant scheme to commercialize new products, processes and services. The paper will be presented on Sunday June 23rd from 11am-1 pm at the annual conference of the American Society for Microbiology, ASM Microbe 2019, at the Moscone Convention Center in San Francisco.
Learn more: Cannabidiol is a Powerful New Antibiotic
The Latest on: Cannnabidiol
[google_news title=”” keyword=”Cannnabidiol” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cannnabidiol
- How West Virginia is regulating THC, CBD and kratom productson May 8, 2024 at 12:35 pm
West Virginia has tightened regulations for hemp-derived cannabinoid and kratom products, with the latest Legislative Session passing a bill clarifying that authority to regulate the substances ...
- Weekly Rulings: May 1-7on May 8, 2024 at 9:09 am
Every week, the TDN posts a roundup of the relevant Horseracing Integrity and Safety Act (HISA) related rulings from around the country. Among this week's rulings, trainer Pavel Matejka has four ...
- Pakistan bets on a cannabis high as its economy struggleson May 7, 2024 at 10:37 pm
A new regulator aims to legalise hemp growth, while crushing a black market. But is Pakistan too late to the party?
- Could cannabis treat cancer someday? Here's what the science says so faron May 7, 2024 at 9:03 am
For decades, cannabis has been studied for its potential antitumor properties, but whether it can actually treat cancer is still unknown.
- How Long Does CBD Stay in Your System?on May 7, 2024 at 5:59 am
CBD has become a popular remedy for pain, inflammation and anxiety without mind-altering effects. But many factors—including dosage and strength—determine how long it stays in your body.
- Best CBD Gummies Of May 2024on May 3, 2024 at 8:18 am
Cannabidiol (CBD) gummies may be appealing to experienced CBD users and newcomers alike as they’re often available in several flavors and strengths.
- Iowa's medical marijuana program is 10 years old. How does it compare with other states?on April 16, 2024 at 4:33 am
Ten years ago this month, Iowa policymakers made it legal to use cannabis for certain medical treatment, marking the start of what would eventually become Iowa's existing medical cannabidiol program.
- Cannabidiol for behavior symptoms in Alzheimer’s disease (CANBiS-AD): a randomized, double-blind, placebo-controlled trialon April 7, 2024 at 5:00 pm
Latha Velayudhan [Opens in a new window], Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK South London & Maudsley NHS Foundation Trust, UK Correspondence should ...
- Target audience: Cannabidiol (CBD) users in Italyon January 30, 2024 at 7:50 am
This report offers the reader a comprehensive overview of cannabidiol (CBD) users in Italy: who they are; what they like; what they think; and how to reach them. It provides insights on their ...
- Harmony buys cannabidiol firm Zynerba in $200m dealon August 14, 2023 at 5:00 pm
Neuroscience specialist Harmony Biosciences has agreed to acquire Zynerba, adding its cannabidiol (CBD) gel product Zygel for Fragile X syndrome and other rare neuropsychiatric disorders to its ...
via Bing News